Shawn Lawrence has been a biochemical engineer at Regeneron Pharmaceuticals, Inc., for 20 years primarily focusing on biopharmaceutical process development with a strong emphasis on science. He currently leads the Cell Culture Development group that has developed the cell culture processes used for the production of over half a dozen commercial therapeutics, dozens of therapeutics in clinical trials including bispecific antibodies, and rapid infectious disease response therapeutics, including Ebola and COVID-19. These efforts have resulted in a record of accomplishment in cell culture medium development and process development using Quality by Design (QbD) principles and their incorporation into subsequent manufacturing activities and regulatory filings. Prior to his work at Regeneron, Shawn received a Ph.D. in Chemical Engineering working on humanizing insect cell produced glycoproteins from the Johns Hopkins University performing research in the Betenbaugh labs.